Nilotinib Hydrochloride Hydrate

盐酸尼洛替尼

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameNilotinib Hydrochloride Hydrate
Drug Alias Name盐酸尼罗替尼一水合物nilotinibum尼洛替尼盐酸盐尼罗替尼盐酸盐尼罗替尼盐酸盐一水合物 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsSkin MelanomaScleroderma, SystemicHypereosinophilic Syndrome +[34] 
Global Approved IndicationsLeukemia, Myelogenous, Chronic
Approved Indications in ChinaLeukemia, Myelogenous, Chronic
Original Approved Country/TerritorySwitzerland
Original Approved Date2007/07/01
Country/TerritoryCzechiaBelgiumBulgaria +[56] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversityLudwig Maximilians University Of MunichNovartis Pharma Schweiz Ag +[9] 
Inactive CompaniesDana-Farber Cancer InstitutePharmaceutical Research Institute Of Huazhong University Of Science And TechnologyWeill Medical College of Cornell University +[13] 
Active IndicationsAlzheimer DiseaseLewy Body DiseaseSynovitis, Pigmented Villonodular +[8] 
Inactive IndicationsSkin MelanomaScleroderma, SystemicHypereosinophilic Syndrome +[26] 

Other Information

ATC CodeL01EA03
Related LinksWikipediaDrugBankKEGG